MktsMarkets

Rapport Therapeutics, Inc.
NASDAQ: RAPPKey statistics
RAPP News
Stories mentioning RAPP from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 20,000 | 0.00 | ||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | ||||||||
| Research & Development | 32,716 | 30,258 | 22,279 | 22,680 | 19,572 | 17,199 | 15,543 | 15,689 |
| Sales General & Admin | 11,499 | 7,536 | ||||||
| Total Operating Expenses | 44,215 | 38,509 | 29,986 | 29,496 | 27,108 | 23,521 | 21,640 | 20,800 |
| Operating Income (Loss) | (24,215) | (38,509) | (29,986) | (29,496) | (27,108) | (23,521) | (21,640) | (20,800) |
| Interest Income | 4,358 | 4,746 | 3,061 | 2,764 | 3,045 | 3,541 | 4,103 | 2,679 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (17,537) | (18,121) | ||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (19,857) | (33,763) | (26,925) | (26,732) | (24,063) | (19,980) | (17,537) | (18,121) |
| Earnings Per Share (Basic) | (0.42) | (0.87) | (0.71) | (0.75) | (0.68) | (0.96) | (0.50) | (1.70) |
| Earnings Per Share (Diluted) | (0.42) | (0.87) | (0.71) | (0.75) | (0.68) | (0.96) | (0.50) | (1.70) |
| Weighted Average Shares Outstanding (Basic) | 47,237 | 38,935 | 37,931 | 35,445 | 35,267 | 20,738 | 34,856 | 10,667 |
| Weighted Average Shares Outstanding (Diluted) | 47,237 | 38,935 | 37,931 | 35,445 | 35,267 | 20,738 | 34,856 | 10,667 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About RAPP
Rapport Therapeutics, Inc. (NASDAQ: RAPP) is a stock listed on the Nasdaq Stock Market under the ticker symbol RAPP. It last traded at $25.96 (Nov 10, 2026, 4:00 PM ET), down 0.4% on the day. That gives Rapport Therapeutics a market capitalisation of $1.5B.
Over the past 52 weeks RAPP has traded between $22.06 and $52.93.
Revenue for the quarter ended Mar 31, 2026 was $20.0M; a net loss of $19.9M.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $20.0M | -$19.9M | -99.3% |
| Dec 31, 2025 | — | -$33.8M | — |
| Sep 30, 2025 | — | -$26.9M | — |
| Jun 30, 2025 | — | -$26.7M | — |
From Rapport Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…